The market was valued at USD 3.35 billion in 2024 and is projected to reach USD 9.18 billion by 2035, growing at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025–2035.
Global Bioanalytical Testing Services in CRO Market Size, Trend & Opportunity Analysis Report, by Molecule (Small, Large), Test (Bioavailability, Bioequivalence), and Forecast, 2025-2035
Report Code: LSDB201Author Name: Isha PaliwalPublication Date: August 2025Pages: 293
Available In:
Global Bioanalytical Testing Services in CRO Market Size, Opportunity Analysis and Forecast, 2025-2035
Publication Date: Aug 26, 2025Pages: 293
Market Definition and Introduction
The Global Bioanalytical Testing Services in the CRO Market were valued at USD 3.35 billion in 2024 and are projected to reach USD 9.18 billion by 2035, growing at an impressive CAGR of 9.6% during the forecast period 2025-2035. Bioanalytical testing services have established themselves as paramount in today's drug development value chain. The services enable pharmaceutical and biotechnology companies to accelerate timelines and hence comply with regulatory requirements while bringing quality therapeutics into the market. Such services can be defined as a large gamut of laboratory-based analytical techniques used for the quantification of drugs, metabolites, and biomarkers from biological matrices to support critical regulatory submissions.
The increasing complexity of drug molecules and the rising pipeline of biologics and small molecules have created demand for bioanalytical capabilities in outsourcing. CROs (Contract Research Organizations) are strategic partners in the R&D of pharmaceuticals, offering scalable, compliant, and technology-based platforms for bioanalytical testing. This trend of outsourcing places an ever-expanding burden on the already high-cost environment, with urgent needs for specialized expertise on the fast track for drug-to-market cycles.
Increased scrutiny from regulatory authorities like the FDA, EMA, and PMDA is also inevitable for pharmacokinetics and pharmacodynamics, wherein assay development needs to be precise and reproducible. Thus, these requirements force the CROs to invest in cutting-edge analytical instrumentation, bioinformatics capabilities, and advances in assay validation. With personalized medicine and biogenerics finding acceptance in the mainstream, we foresee an exponential growth of bioanalytical testing services for niche but highly regulated therapeutic areas.
Recent Developments in the Industry
- In January 2024, Labcorp announced a substantial extension of its bioanalytical laboratory infrastructure, with new LC-MS/MS platforms and ligand-binding assay technologies to support increased demand for biologics and biosimilar testing.
- In March 2024, ICON launched an integrated suite of bioequivalence testing solutions that incorporate real-time data analytics, adaptive trial designs, and enhanced patient recruitment strategies to expedite generic submissions.
- In May 2024, Eurofins acquired a leading, APAC-based CRO specialized in pharmacokinetics and bioavailability testing to enlarge its service footprint in the high-growth emerging markets.
Market Dynamics
Accelerating shift toward outsourcing as pharmaceutical companies streamline R&D pipelines
The increasing complexity of drug discovery and stiff competition around timelines have pushed pharma and biotech companies to partner more with CROs for bioanalytical testing. This gives sponsors flexibility and access to specialized analytical capabilities without the burden of establishing an expensive infrastructure.
Growing regulatory emphasis on robust bioequivalence and bioavailability data for drug approvals
The tightening of global regulatory frameworks means that the generation of high-quality and reproducible bioanalytical data by drug developers has become mandatory. This, in turn, has stimulated an increased demand for CROs with demonstrable regulatory track records along with validated methodologies across various therapeutic areas.
Advancements in analytical technologies are driving enhanced accuracy and throughput in testing services.
With various advances adopted in high-resolution mass spectrometry, sample preparation automation, and bioinformatics, there now exists a significant increase in the precision, sensitivity, and turnaround times of bioanalytical assay testing. These improvements are being adopted by CROs in keeping with increasingly demanding standards of the industry.
Rising biologics and biosimilars pipeline boosting demand for large molecule bioanalytical testing
As the market for monoclonal antibodies, recombinant proteins, and biosimilars expands, specialized services for large molecules in bioanalysis, such as ligand-binding assays and cell-based assays, gain importance in fulfilling the development milestones.
Attractive Opportunities in the Market
- Advanced LC-MS/MS Applications - Expanding role in both small and large molecule quantification
- Biosimilar Growth - Rising demand for ligand-binding assays in biosimilar development
- Asia-Pacific Expansion - Emerging CRO hubs driving competitive pricing and scalability
- Integrated Service Models - Full-spectrum PK/PD, immunogenicity, and biomarker testing in one platform
- Digital Transformation - AI-driven analytics and e-source integration enhancing operational efficiency
- Rare Disease Focus - Specialized assays for orphan drug approvals gaining market traction
- Regulatory Harmonization - Streamlined multi-country approval pathways boosting CRO demand
- Strategic Partnerships - Collaborations between CROs and biotech firms enabling end-to-end solutions
Report Segmentation
By Molecule: Small, Large
By Test: Bioavailability, Bioequivalence
By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)
Key Market Players: Labcorp Drug Development, Charles River Laboratories, ICON plc, Syneos Health, SGS SA, WuXi AppTec, PPD (a Thermo Fisher Scientific company), Eurofins Scientific, Medpace, and IQVIA.
Report Aspects
Base Year: 2024
Historic Years: 2022, 2023, 2024
Forecast Period: 2024-2035
Report Pages: 293
Dominating Segments
The large molecule segment gathers momentum for its increasingly large biologics and biosimilars development pipelines.
Rapid growth in large molecule bioanalytical testing has been because of increased traction toward biologics, such as monoclonal antibodies, recombinant proteins, and cell-based therapies addition, CROs heavily invest in ligand-binding assays, immunogenicity testing as well and biomarker analysis to fulfill the multifaceted analytical requirements of these therapies.
The bioequivalence testing segment is the top dog among markets with generic as well as complex generic approvals.
The resultant increase in demand for bioequivalence testing services derives from multitudes of generic drug submissions pouring in with the flow of emerging nations. Accordingly, CROs have adopted the modern design of adaptive trial methodology, efficient recruitments, and lots more advanced analytics platforms to feed the regulatory-compliant data.
Small molecule testing remains firm because bulk traditional drugs have been applied to this testing.
Though the thrust is towards biologics, small-molecule bioanalytical tests continue to maintain their leadership in volume because of a steady flow of both oral and injectable pharmaceuticals in the pipeline. LC-MS/MS and hybridization assays are still retained as indispensable instruments in pharmacokinetic profiling as well as in toxicity evaluation.
Key Takeaways
- Large Molecule Ascendancy - Rising biologics and biosimilars drive specialized assay development
- Bioequivalence Dominance - Regulatory emphasis on generics accelerates service demand
- Tech-Driven Accuracy - Advanced LC-MS/MS and automation enhance precision and throughput
- Outsourcing Surge - CRO partnerships enable cost-effective, scalable solutions
- Regulatory Pressure - Stringent FDA and EMA guidelines elevate service quality benchmarks
- Asia-Pacific Growth - Emerging markets becoming competitive hubs for testing services
- Integrated Solutions - Combined PK/PD, immunogenicity, and biomarker testing boosts client retention
- Competitive M&A - Consolidation enhances global reach and service diversification
- Rare Disease Expansion - Orphan drug testing services gain strategic importance
- Digital Integration - AI-enabled data analysis streamlining workflows and decision-making
Regional Insights
Strong Infrastructure and Regulatory Expertise Define North American Leadership
North America, spearheaded by the U.S., is certainly a leader in the global bioanalytical testing services market for its highly effective pharmaceutical R&D ecosystem, its large volume of clinical trial activities, and the stringently defined regulations that it mandates. The CROs in the region do comprise advanced instrumentalization and digital workflows for the provision of unmatched quality of service and compliance.
Regulatory Alignment and Innovations in Biosimilar Testing: Europe's Lead
The stronghold of Europe in bioanalytical testing is well maintained through the well-established biosimilar development framework and adherence to EMA stringent assay validation guidelines. The region is also a strong leader in harmonizing the regulatory practices to promote efficient cross-border drug development projects.
Asia-Pacific is the Growing Market: Expanding CRO Capabilities as Growth Drivers
Asia-Pacific is about to have rapid growth because of the cost-competitive services, rapidly growing pharmaceutical manufacturing hubs, and favorable government policies. A few of the major countries in this segment are China, India, and South Korea, which are setting up high-throughput testing infrastructures to bring in major outsourcing contracts.
Key Benefits for Stakeholders
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
Frequently Asked Questions
The large molecule segment is gathering significant momentum due to an expanding pipeline of biologics and biosimilars, including monoclonal antibodies, recombinant proteins, and cell-based therapies. This shift is driving increased investment in ligand-binding assays and immunogenicity testing.
The shift is driven by the increasing complexity of drug discovery, stiff competition regarding development timelines, and the need for pharmaceutical companies to access specialized analytical expertise and advanced infrastructure without the high costs of establishing in-house facilities.
Advancements in high-resolution mass spectrometry (LC-MS/MS), sample preparation automation, and bioinformatics are significantly enhancing the precision, sensitivity, and turnaround times of assay testing, allowing CROs to meet increasingly stringent industry standards.
North America, led by the U.S., is the market leader due to its highly effective pharmaceutical R&D ecosystem, a high volume of clinical trial activities, and a robust regulatory framework that mandates sophisticated instrumentalization and digital workflows.
Bioequivalence testing is a dominant segment, particularly for generic and complex generic drug approvals. The surge in generic drug submissions, especially from emerging nations, has led CROs to adopt adaptive trial methodologies and advanced analytics to provide regulatory-compliant data.
The major players identified in the industry include Labcorp Drug Development, Charles River Laboratories, ICON plc, Syneos Health, SGS SA, WuXi AppTec, PPD (a Thermo Fisher Scientific company), Eurofins Scientific, Medpace, and IQVIA.
Key challenges include the high capital investment required for advanced analytical instrumentation, variability in regulatory requirements across different jurisdictions, a shortage of highly specialized talent, and intense pricing competition among CROs.
Significant opportunities include the expansion of services for rare diseases and orphan drugs, the adoption of AI-driven analytics for faster decision-making, the growth of integrated service models (combining PK/PD and immunogenicity), and the rising demand for biosimilar testing in the Asia-Pacific region.
In early 2024, Labcorp expanded its laboratory infrastructure with new LC-MS/MS platforms; ICON launched an integrated suite for bioequivalence testing featuring real-time data analytics; and Eurofins acquired an APAC-based CRO to enhance its footprint in high-growth emerging markets.
